Mistaurin 25MG Soft Gelatin Capsule (4’s) is a specialized medication that contains Midostaurin, a potent active ingredient known for its role in treating specific types of cancer. This drug is primarily indicated for patients with acute myeloid leukemia (AML) and advanced systemic mastocytosis, conditions characterized by the uncontrolled growth of abnormal blood cells. Each soft gelatin capsule contains 25 mg of Midostaurin, which is designed to be easily absorbed by the body, enhancing its therapeutic effects. Mistaurin works by inhibiting certain proteins that promote cancer cell growth, thereby slowing down or stopping the progression of the disease. The formulation is designed for optimal bioavailability, ensuring that patients receive the maximum benefit from each dose. As a targeted therapy, Mistaurin represents a significant advancement in cancer treatment, offering hope to patients facing challenging diagnoses.

Mylotarg Injection (4.5mg), which contains the active ingredient Gemtuzumab ozogamicin, is a targeted therapy used primarily in the treatment of acute myeloid leukemia (AML), particularly in patients with specific genetic markers. This medication is a conjugate of a humanized monoclonal antibody and a cytotoxic agent, designed to deliver the chemotherapy drug directly to cancer cells, thereby minimizing damage to healthy cells. Mylotarg works by binding to CD33, a protein commonly found on the surface of leukemia cells, facilitating the internalization of the cytotoxic agent and leading to cell death. The injection is typically administered in a clinical setting under the supervision of healthcare professionals, ensuring that patients receive the appropriate dosage and monitoring for any adverse effects. Mylotarg is an important option for patients with relapsed or refractory AML, offering a targeted approach to treatment that can improve outcomes and quality of life.